Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun 14;39(6):750-752.
doi: 10.1016/j.ccell.2021.05.012.

Using real-word data to evaluate the effects of broadening eligibility criteria in oncology trials

Enrique Sanz-Garcia  1 , Benjamin Haibe-Kains  2 , Lillian L Siu  3
Affiliations
Free article
Comment

Using real-word data to evaluate the effects of broadening eligibility criteria in oncology trials

Enrique Sanz-Garcia et al. Cancer Cell. .
Free article

Abstract

Eligibility criteria restrict patient enrollment in clinical trials. A Nature paper applied a machine-learning algorithm in a real-world database to show that relaxing some criteria may not jeopardize efficacy and safety. This may enable more patients to have earlier access to new therapies and make results more generalizable to clinical practice.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Enrique Sanz-Garcia declares no competing interests. Benjamin Haibe-Kains has consulting arrangements with Code Ocean Inc. Lillian L. Siu has consulting/advisory arrangements with Merck, Pfizer, Celgene, AstraZeneca, Morphosys, Roche, Oncorus, Symphogen, Seattle Genetics, GlaxoSmithKline, Voronoi, Arvinas, Tessa, Navire, Relay, Rubius, Janpix, and Daiichi Sanyko; stock ownership of Agios (spouse); and a leadership position in Treadwell Therapeutics (spouse); and her institution receives clinical trials support from Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati Therapeutics, Shattucks, and Avid.

Comment on

Publication types

LinkOut - more resources